Myriad Genetics, Inc.
Business Overview: Myriad Genetics, Inc. (Nasdaq: MYGN)
Executive Summary
Myriad Genetics, Inc. is a molecular diagnostics and precision-medicine company headquartered in Salt Lake City, Utah, with additional laboratory operations in South San Francisco, California, and Mason, Ohio. Described in its own filing as "a pioneer in DNA-based cancer diagnostic testing," Myriad built its franchise on hereditary cancer risk testing and has since expanded into companion diagnostics, prenatal and carrier screening, and pharmacogenomics.
The company organizes its test portfolio around three areas — Oncology, Women's Health, and Mental Health — and employed roughly 2,700 full-time equivalent employees as of the end of 2025. Myriad matters because its tests sit at decision points that directly affect patient treatment: whether a patient should receive a targeted cancer therapy, whether a pregnancy carries elevated genetic risk, or which psychiatric medication is likely to work for a given patient's metabolism.
1. Core Business Model & How They Work
[ Proprietary Genetic/Molecular Assay Development ] ➡️ [ CLIA-Certified Lab Processing (Utah, California, Ohio) ] ➡️ [ Direct Sales Force + Payer Reimbursement ] ➡️ [ Clinical Report to Physician/Patient ] ➡️ [ Treatment or Screening Decision ]Myriad sells primarily through a direct sales force and marketing organization in the U.S. and Japan, supplemented by indirect channels and partnerships in Europe and Asia-Pacific. Revenue depends heavily on payer reimbursement for its tests, and the company has invested in EMR integrations and digital ordering/reporting tools to make it easier for physicians to order tests and receive results inside their existing clinical workflows — a meaningful driver of repeat ordering behavior.
2. Business Segments (by Clinical Area)
┌────────────────────────────────────┐
│ Myriad Genetics, Inc. │
└──────────────────┬────────────────────┘
┌────────────┼─────────────┐
▼ ▼ ▼
┌─────────────┐┌──────────────┐┌──────────────┐
│ Oncology ││ Women's Health││ Mental Health │
│ MyRisk, ││ MyRisk, ││ GeneSight │
│ BRACAnalysis ││ Prequel, ││ (pharmaco- │
│ CDx, MyChoice││ Foresight, ││ genomics) │
│ CDx, Prolaris││ FirstGene, ││ │
│ Precise Tumor││ SneakPeek ││ │
│ /MRD ││ ││ │
└─────────────┘└──────────────┘└──────────────┘Oncology
Hereditary cancer risk assessment (MyRisk), companion diagnostics tied to specific cancer drugs (BRACAnalysis CDx, MyChoice CDx), prognostic tests (Prolaris), and tumor/minimal-residual-disease monitoring (Precise Tumor, Precise MRD). EndoPredict was divested in August 2024, with U.S. sales winding down through the first half of 2026.
Women's Health
MyRisk for hereditary risk, Prequel (non-invasive prenatal screening), Foresight (carrier screening), SneakPeek (early fetal sex testing), and FirstGene — a 4-in-1 prenatal screen expected to reach full commercial launch in 2026.
Mental Health
GeneSight, a pharmacogenomic test that helps clinicians choose psychotropic medications based on a patient's genetic metabolism profile.
3. Product Portfolio
| Test | Clinical Area | Purpose | Why It Matters |
|---|---|---|---|
| MyRisk | Oncology / Women's Health | Multi-gene hereditary cancer risk panel | Myriad's founding franchise and still a core volume driver |
| BRACAnalysis CDx / MyChoice CDx | Oncology | Companion diagnostics identifying patients eligible for specific targeted therapies | Ties Myriad directly into biopharma drug-development and commercialization partnerships |
| Prequel / Foresight / FirstGene | Women's Health | Prenatal screening and carrier screening | Growing franchise with FirstGene's 2026 launch as a near-term catalyst |
| GeneSight | Mental Health | Pharmacogenomic-guided psychiatric prescribing | A differentiated, largely stand-alone franchise versus Myriad's cancer-testing peers |
| Precise Tumor / Precise MRD | Oncology | Tumor profiling and minimal-residual-disease monitoring | Positions Myriad in the fast-growing MRD-monitoring category alongside specialists like Natera and Guardant |
4. Competitive Landscape
BROAD DIAGNOSTICS <——————————→ FOCUSED PRECISION TESTING
National labs │ LabCorp, Quest Diagnostics │
│ [ MYRIAD GENETICS ] │
Specialized │ Natera, Foundation Medicine, Tempus, │
genomics/oncology │ Caris Life Sciences, Guardant Health, │
competitors │ Veracyte, NeoGenomics, MDxHealth │
│ │
Women's Health / │ BillionToOne, Fulgent Genetics, Peekaboo │
Mental Health │ Genomind, Tempus AI │
specialists │ │Myriad faces a crowded and well-funded competitive field across all three of its clinical areas: in Oncology, against Natera, Foundation Medicine, Caris Life Sciences, Tempus, LabCorp, Quest, Veracyte, Guardant Health, MDxHealth, and NeoGenomics; in Women's Health, against Natera, LabCorp, Quest, BillionToOne, Tempus AI, Fulgent Genetics, and Peekaboo; and in Mental Health, against Genomind, Tempus AI, Quest, and LabCorp. Natera and Tempus in particular appear across multiple categories, underscoring how several well-capitalized competitors are expanding into adjacent testing areas that overlap with Myriad's historical strongholds.
5. Strategic Strengths & Risks
Strengths (The Moat)
- Decades of proprietary variant data: Myriad's long history in hereditary cancer testing has built a large, proprietary database of genetic variant classifications that improves the accuracy of its risk assessments — a genuine data-driven advantage that is slow for newer entrants to replicate.
- Companion-diagnostic partnerships: tests like BRACAnalysis CDx and MyChoice CDx are tied directly to specific approved cancer drugs, embedding Myriad into the biopharma commercialization process in a way that is hard to displace once a drug's label references the test.
- EMR and digital-ordering integration: investment in workflow tools that sit inside physicians' existing systems increases the friction of switching to a competing lab for routine ordering.
Risks
- Intensifying competition across every category: Natera, Tempus, and LabCorp/Quest all compete across multiple Myriad clinical areas simultaneously, and some (Natera, Tempus) are growing rapidly and well-capitalized.
- Reimbursement dependency: as with all molecular diagnostics companies, Myriad's revenue is exposed to payer coverage decisions and reimbursement-rate pressure outside its direct control.
- Product transitions carry execution risk: the EndoPredict divestiture and FirstGene's 2026 full commercial launch both represent near-term portfolio transitions that could disrupt revenue if not executed cleanly.
- R&D spending trend: R&D expense declined from $113.4 million (2024) to $106.8 million (2025), after rising from $88.7 million in 2023 — a pattern worth watching given how competitive the broader genomic-testing field has become.
6. Financial Overview
| Metric | FY2025 | FY2024 | FY2023 | Strategic Context |
|---|---|---|---|---|
| R&D expense | $106.8M | $113.4M | $88.7M | Pipeline investment moderated slightly in 2025 after a sharp 2024 increase |
| Full-time equivalent employees | ~2,700 | — | — | Scale of lab and commercial operations |
| Shares outstanding | 93,508,165 (2/19/2026) | — | — | Reference for market capitalization |
The fetched filing excerpt did not include total revenue or net income figures; those are not reported here to avoid presenting unverified numbers.
7. Summary Conclusion
Myriad Genetics has built a genuine, if increasingly contested, moat around decades of proprietary genetic-variant data and companion-diagnostic ties to specific approved cancer drugs — advantages that are real but no longer unique, as well-funded competitors like Natera and Tempus push into Oncology, Women's Health, and adjacent categories simultaneously. The company's path forward depends on converting its historical data and clinical-workflow integration advantages into durable share in newer growth areas (MRD monitoring, expanded prenatal screening) faster than its rivals can close the gap.